Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Oncology

• Publication date

  2014-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/ijo.2014.2545PMID 25051198
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Linear ubiquitination: a newly discovered regulator of cell signalling.

  2013cited by this paper
• E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis

  2013cited by this paper
• Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

  2013cited by this paper
• Prostate cancer incidence and mortality in rural men--a systematic review of the literature.

  2012cited by this paper
• Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1

  2011cited by this paper
• Transcription alterations of members of the ubiquitin–proteasome network in prostate carcinoma

  2011cited by this paper
• The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling

  2011cited by this paper
• SMURF and NEDD4: Sharp Shooters Monitor the Gate Keepers and Ion Traffic Controllers of Lead Astray Cell

  2011cited by this paper
• Real-time reverse transcription-polymerase chain reaction quantification of tumor necrosis factor alpha messenger in human leukocytes.

  2011cited by this paper
• Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with distinct physiological functions

  2010cited by this paper
• RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes

  2008cited by this paper
• Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.

  2008cited by this paper
• The potential of proteasome inhibitors in cancer therapy

  2008cited by this paper
• The HECT family of E3 ubiquitin ligases: multiple players in cancer development.

  2008cited by this paper
• TGF-beta and BMP7 interactions in tumour progression and bone metastasis.

  2007cited by this paper
• The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.

  2007cited by this paper
• In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma

  2007cited by this paper
• Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease

  2007cited by this paper
• Bortezomib inhibits osteoclast activity in patients with multiple myeloma.

  2007cited by this paper
• Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer

  2007cited by this paper
• TGF-β and BMP7 interactions in tumour progression and bone metastasis

  2007cited by this paper
• The Nedd4-like family of E3 ubiquitin ligases and cancer

  2007cited by this paper
• United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

  2006cited by this paper
• Regulation of Adult Bone Mass by the Zinc Finger Adapter Protein Schnurri-3

  2006cited by this paper
• Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases

  2005cited by this paper
• Bortezomib as a Potential Treatment for Prostate Cancer

  2004cited by this paper
• Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003cited by this paper
• Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads.

  2003cited by this paper
• Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro.

  2003cited by this paper
• Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.

  2001cited by this paper
• Autocrine expression of neurotrophins and their receptors in prostate cancer

  2001cited by this paper
• Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

  2001cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper

• SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics

  2026cites this paper
• Expression of SMURF family in pancreatic cancer and its effect on cell proliferation and migration

  2025cites this paper
• Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment

  2025cites this paper
• Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma

  2025cites this paper
• The role of WWP1 and WWP2 in bone/cartilage development and diseases

  2024cites this paper
• Cross-ancestry meta-genome-wide association studies provide insights to the understanding of semen traits in pigs.

  2024cites this paper
• Targeting the WWP1 gene with incensole acetate nanoemulsion: A novel therapeutic strategy for breast cancer

  2024cites this paper
• Immunohistochemical Expression and Clinical Significance of WWP1 Protein in Nasopharyngeal Cancer

  2024cites this paper
• The role of SMURFs in non‐cancerous diseases

  2023cites this paper
• NEDD4 E3 ubiquitin ligases: promising biomarkers and therapeutic targets for cancer.

  2023cites this paper
• WWP1 E3 ligase at the crossroads of health and disease

  2023cites this paper
• Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer

  2022cites this paper
• Smurf2 suppresses the metastasis of hepatocellular carcinoma via ubiquitin degradation of Smad2

  2022cites this paper
• Translational Strategies to Target Metastatic Bone Disease

  2022cites this paper
• The intricate interplay between HIFs, ROS, and the ubiquitin system in the tumor hypoxic microenvironment.

  2022cites this paper
• Leucine zipper protein 2 serves as a prognostic biomarker for prostate cancer correlating with immune infiltration and epigenetic regulation

  2022cites this paper
• Mechanisms, Diagnosis and Treatment of Bone Metastases

  2021cites this paper
• Exploring the Roles of HERC2 and the NEDD4L HECT E3 Ubiquitin Ligase Subfamily in p53 Signaling and the DNA Damage Response

  2021cites this paper
• The emerging role of WWP1 in cancer development and progression

  2021cites this paper
• The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocytes

  2021cites this paper
• Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges

  2021cites this paper
• The efficacy and mechanism of proteasome inhibitors in solid tumor treatment.

  2021cites this paper
• Bortezomib Rescues Ovariectomy-Induced Bone Loss via SMURF-Mediated Ubiquitination Pathway

  2021influential citation
• Proteostasis and Disease: From Basic Mechanisms to Clinics

  2020cites this paper
• SMURF1, a promoter of tumor cell progression?

  2020cites this paper
• WWP1在慢性淋巴细胞白血病中的异常表达及临床意义

  2020cites this paper
• IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way

  2020cites this paper
• Divergent Modulation of Proteostasis in Prostate Cancer.

  2020cites this paper
• The functions and regulations of Smurfs in cancers.

  2019cites this paper
• Resveratrol induces depletion of TRAF6 and suppresses prostate cancer cell proliferation and migration.

  2019cites this paper
• Bortezomib attenuates renal interstitial fibrosis in kidney transplantation via regulating the EMT induced by TNF‐α‐Smurf1‐Akt‐mTOR‐P70S6K pathway

  2019cites this paper
• PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance.

  2019cites this paper
• The Proteasome and Myeloma-Associated Bone Disease

  2018cites this paper
• Suppression of the Smurf1 Expression Inhibits Tumor Progression in Gliomas

  2018cites this paper
• WW domain-containing E3 ubiquitin protein ligase 1 depletion evokes antitumor effect in cutaneous squamous cell carcinoma by inhibiting signal transducer and activator of transcription 3 signaling pathway

  2018cites this paper
• Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer

  2016cites this paper
• Tudor tells about new twists in the story tale of SMURFs.

  2016cites this paper
• Caractérisation d'un nouveau mécanisme d'action de la E3 ubiquitine ligase WWP1 et régulation de son activité dans la cancérogenèse

  2015cites this paper
• Molecular functions of NEDD4 E3 ubiquitin ligases in cancer.

  2015cites this paper